Publications by authors named "Carolyn Winskill"
Introduction: Many individuals who previously received negative genetic test results are eligible for updated testing. This study examined intention to communicate updated genetic test results to relatives in participants who previously received negative genetic test results.
Methods: Women with a personal or family history of breast or ovarian cancer who tested negative for BRCA1/2 before 2013 were enrolled between April 2018 and October 2019.
Article Synopsis
- - The study investigated the effectiveness and safety of biologic treatments for moderate-to-severe psoriasis in children, comparing results from pediatric random controlled trials to data from adults.
- - A systematic literature review identified multiple RCTs for different biologics in children, revealing that all biologics improved PASI (Psoriasis Area Severity Index) scores compared to control groups, with ustekinumab and ixekizumab showing the highest efficacy.
- - Adverse events were generally low in both pediatric and adult groups, with side effects ranging from 0 to 3%, though a higher incidence (8%) was noted in a specific pediatric study using adalimumab.
There is currently no targeted therapy to treat NF1-mutant melanomas. In this study, we compared the genomic and transcriptomic signatures of NF1-mutant and NF1 wild-type melanoma to reveal potential treatment targets for this subset of patients. Genomic alterations were verified using qPCR, and differentially expressed genes were independently validated using The Cancer Genome Atlas data and immunohistochemistry.
View Article and Find Full Text PDFBackground: Juvenile idiopathic arthritis (JIA) is one of the most common pediatric inflammatory rheumatic diseases (PiRDs). Uncontrolled disease activity is associated with decreased quality of life and chronic morbidity. Biologic disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi) have considerably improved clinical outcomes.
View Article and Find Full Text PDFAnti-vascular endothelial growth factor (VEGF) therapy is used to slow the disease progression of neovascular age-related macular degeneration. Due to the treatment burden of frequent intravitreal injections, anti-VEGFs are often used on treat and extend protocols rather than the labeled frequency. The current goal of anti-VEGF drug development is to minimize treatment burden by reducing the number of intravitreal injections.
View Article and Find Full Text PDFArticle Synopsis
- The study explores the use of biologic disease modifying antirheumatic drugs (bDMARDs) and Janus Kinase (JAK) inhibitors in pediatric patients with inflammatory rheumatic diseases (PiRD), highlighting their differences from adult patients due to age-related factors.
- A systematic review identified 35 randomized clinical trials (RCTs) involving PiRD, focusing on efficacy, safety outcomes, and pharmacokinetics of various treatments, particularly TNF inhibitors, IL-1 inhibitors, and IL-6 inhibitors.
- Most trials were conducted for juvenile idiopathic arthritis (JIA), with treatments often compared to placebo, and a variety of ongoing studies are investigating additional bDMARDs